Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "RAS"

1406 News Found

Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years
Policy | August 10, 2024

Jan Aushadhi Kendras have sold Rs. 5,600 Cr medicines over last 10 years

The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024


Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr
News | August 06, 2024

Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr

Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024


Health Ministry issues advisory to states in view of zika virus cases from Maharashtra
Policy | July 04, 2024

Health Ministry issues advisory to states in view of zika virus cases from Maharashtra

States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika


CCRAS hosts national consultative meet on traditional medicine
Policy | June 26, 2024

CCRAS hosts national consultative meet on traditional medicine

Signs MoUs with Shri Krishna Ayush University and Dabur India


CCRAS to organize national consultative meet on ‘Research Priority Settings in Traditional Medicine’ in collaboration with WHO
Policy | June 24, 2024

CCRAS to organize national consultative meet on ‘Research Priority Settings in Traditional Medicine’ in collaboration with WHO

The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India


Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
Clinical Trials | May 27, 2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression


KRAZATI in Combination with Cetuximab demonstrates targeted treatment option for KRAS G12C- colorectal cancer
Clinical Trials | April 11, 2024

KRAZATI in Combination with Cetuximab demonstrates targeted treatment option for KRAS G12C- colorectal cancer

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program


Shivalik Rasayan’s API facility gets 7 observations from USFDA
Drug Approval | April 10, 2024

Shivalik Rasayan’s API facility gets 7 observations from USFDA

These observations are procedural in nature and will be responded within the stipulated time


Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
Clinical Trials | April 05, 2024

Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084

For the first-line treatment of certain patients with metastatic non-small cell lung cancer


Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data
Drug Approval | April 01, 2024

Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024